Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
|Articles|February 19, 2014
Equipment and Processing Report
- Equipment and Processing Report-02-19-2014
- Volume 0
- Issue 0
Omega Design Corporation System Prints and Verifies Unit-Level Data on Cartons
The Intelli-Code Carton Coding and Inspection System connects to serialization data-management systems.
Omega Design Corporation’s Intelli-Code Carton Coding and Inspection System prints unit-level data on individual cartons using thermal ink-jet or laser printing and employs an integrated vision system to verify printed data. The system can be incorporated into new or existing carton lines or deployed as part of an independent serialization cell. It supports a variety of customer choices regarding preferred printing technologies, camera and inspection vision systems, and connectivity to serialization software from a variety of providers.
Source:
Articles in this issue
over 12 years ago
Complying with Revised USP Chapters on Weighingover 12 years ago
Schreiner MediPharm Introduces SecuMed Labeling Systemover 12 years ago
Developments in Producing MicrospheresRelated to this article
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5